News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus
FDA has set Prescription Drug User Fee Act (PDUFA) target action date of August 23, 2021 If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patients STAMFORD, Conn , and ST. GALLEN , Switzerland , March 08, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics
View HTML
Toggle Summary Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
– U.S. FDA Accepts NDA Filing for KORSUVA™ Injection in CKD-aP – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed
View HTML
Toggle Summary Cara Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
STAMFORD, Conn. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that
View HTML
Toggle Summary Cara Initiates Phase 2 Trial of Oral KORSUVA™ for the Treatment of Pruritus in Patients with Notalgia Paresthetica
Expands clinical development of Oral KORSUVA™ into neuropathic pruritus STAMFORD, Conn. , Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by
View HTML
Toggle Summary Cara Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced
View HTML
Toggle Summary Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus
First NDA submission for Company’s lead program, KORSUVA™ Injection – NDA submission includes request for Priority Review under Breakthrough Therapy Designation for KORSUVA Injection – STAMFORD, Conn. , Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.
View HTML
Toggle Summary Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
- Topline data expected in first half of 2021   - STAMFORD, Conn. , Dec. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting
View HTML
Toggle Summary Cara Therapeutics to Present at Multiple Upcoming Investor Conferences
STAMFORD, Conn. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today
View HTML
Toggle Summary Cara Therapeutics Reports Third Quarter 2020 Financial Results
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa
View HTML
Toggle Summary Cara Therapeutics to Announce Third Quarter 2020 Financial Results on November 9, 2020
STAMFORD, Conn. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that
View HTML